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Abstract
Allosteric modulators are ligands for proteins that exert their effects via a different binding site than the natural (orthosteric)
ligand site and hence form a conceptually distinct class of ligands for a target of interest. Here, the physicochemical and
structural features of a large set of allosteric and non-allosteric ligands from the ChEMBL database of bioactive molecules
are analyzed. In general allosteric modulators are relatively smaller, more lipophilic and more rigid compounds, though
large differences exist between different targets and target classes. Furthermore, there are differences in the distribution of
targets that bind these allosteric modulators. Allosteric modulators are over-represented in membrane receptors, ligand-
gated ion channels and nuclear receptor targets, but are underrepresented in enzymes (primarily proteases and kinases).
Moreover, allosteric modulators tend to bind to their targets with a slightly lower potency (5.96 log units versus 6.66 log
units, p,0.01). However, this lower absolute affinity is compensated by their lower molecular weight and more lipophilic
nature, leading to similar binding efficiency and surface efficiency indices. Subsequently a series of classifier models are
trained, initially target class independent models followed by finer-grained target (architecture/functional class) based
models using the target hierarchy of the ChEMBL database. Applications of these insights include the selection of likely
allosteric modulators from existing compound collections, the design of novel chemical libraries biased towards allosteric
regulators and the selection of targets potentially likely to yield allosteric modulators on screening. All data sets used in the
paper are available for download.
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The generation of drug-like lead and candidate molecules
against a specific molecular target remains a major challenge in
drug discovery. We are now in a position to partially understand
the factors behind this, and they fall into two basic themes – 1) the
diversity and size of the set of compounds used in the initial screen,
and 2) the physicochemical properties of the binding site of the
target, which may contain obligate features that are incompatible
to binding molecules with drug-like properties [1–7]. There are
now a large number of ‘tantalizing targets’, those that have strong
biological rationale (for example genetic validation), but are
currently outside the reach of the development of novel small
molecule therapies. One strategy to avoid the issues of factor 2)
above is to consider the development of allosteric regulators, which
may have better, or at least differentiated physicochemical
properties or advantages in selectivity and so forth [8–11].
The concept of allosterism has received ample attention in
literature, yet the term is used relatively loosely, the current work
starts by defining the definition of allosterism [8,12–17]. Allosteric
modulators are ligands for a biological target that exert their effect
on this target via a mechanism that is not located at the molecular
site of action of those ligands that are the natural ligands or
substrates for this protein. Hence the term ‘allosteric modulator’
covers a very broad spectrum of compounds and it depends on the
context and function of the protein in question what effect
allosteric modulators truly have. Thus, while some papers have
previously been published classifying allosteric modulators as a
separate class of ligands in general, here it is argued that the
physicochemical properties of the molecules depend equally on the
target in question [11,18].
For example if the target is a signaling protein (e.g. a G protein-
coupled receptor (GPCR)) which naturally signals in response to
ligand binding, an allosteric modulator can induce, inhibit,
increase, or decrease this signal while still allowing the natural
ligand to bind to the receptor (albeit with modified thermody-
namic and kinetic parameters). In some cases the allosteric
modulator can even prevent the natural ligand from binding
through a conformational shift. Similarly, in the case of an
enzyme, an allosteric modulator can increase, decrease, or block
enzyme catalytic activity.
In the case of proteins with multiple functions and active sites,
categorizing ligands as allosteric versus orthosteric can be pro-
blematic. For example, Figure 1 shows cyclin-dependant kinase 2
(CDK2) involved in cell cycle control and known to have multiple
binding sites for which multiple inhibitor types exist [19]. Firstly,
several inhibitors are known to inhibit the protein via the ATP
binding site (which is commonly referred to as orthosteric inhi-
bition, type I inhibition). Hence both ligands in competition with
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the ATP-binding site and proteins in competition with the substrate
to be phosphorylated could be deemed orthosteric but differ
significantly in their physicochemical properties. However, in
literature the latter group is also classified as allosteric inhibitors.
Moreover, one naturally occurring inhibitor of CDK2, cyclin-
dependent kinase inhibitor 1B or cyclin-dependent kinase inhibitor
p27, binds to the complex of CDK2 – cyclin A and protrudes into
the ATP binding site [20].
Conversely, several small molecule classes have been identified
that inhibit protein kinases in an allosteric manner. Type II
inhibitors occupy the nucleotide-binding pocket and extend into
the allosteric pocket, stabilizing the enzymatic inactive conforma-
tion (DFG out), whereas type III inhibitors bind and occupy an
allosteric pocket. Additionally, there are type IV inhibitors that are
covalent inhibitors targeting reactive proximal cysteine residues
[19]. Finally, a fifth class (Type V) of inhibitors have also been
discovered for CDK2. These are non-ATP competitive, but the
binding pocket has been shown to differ from that of known type II
and III inhibitors [21]. The inhibitors have been shown to bind
near the C-helix, which is involved in the interaction of CDK2
with cyclins A and E [22,23]. Binding of these ligands also disrupts
the protein – protein interaction (PPI) between CDK2 and cyclin,
confirming the potential of allosteric modulators to disrupt PPIs.
Hence CDK2 is home to multiple binding sites to which
multiple sets of ligands/substrates can bind in different ways.
These ligands can be orthosteric (ATP-competitive), substrate
competitive peptidomimetic molecules (non-competitive with
regard to ATP, allosteric) or non ATP-competitive small molecules
(allosteric), and can be further subdivided based on the mechanism
of action. For these reasons, and because the approach here relies
on retrieving allosteric papers, the term non-allosteric (rather than
orthosteric) is used to describe other ligands binding to the same
protein than those retrieved in the here described allosteric
dataset. The definition of allosteric follows herein the target in
question and general agreement in the literature; hence any
observations are relative to this agreement in literature. There are
a number of targets for which one can make similar distinctions
with different forms of classification (e.g. in the kinase case one can
define the ATP-competitive ligands as allosteric and only define
the peptidomimetic ligands to be orthosteric). However, as the
current results are derived from and based on medicinal chemistry
literature it is chosen to follow this literature. Please see Case study
4 for further details on applying the here described methods to
Kinase targets.
Allosteric modulators as drugs
As discussed above, the differences in binding site properties
relative to the substrate/agonist/antagonist site are potentially
attractive for operational drug discovery reasons. Allosteric
modulators can hit targets with natural ligands that are outside
classic oral drug-like space (e.g. class B GPCRs), or are difficult to
hit with specificity with regard to paralogs (e.g. class C GPRCs), or
Figure 1. The concept of multiple binding sites on a single protein visualized schematically (A) and in protein data bank structure
1JSU (B). The ATP binding site was shown in green on cyclin dependent kinase 2 (CDK2) (grey), commonly referred to as the orthosteric binding site.
One allosteric binding site (type V inhibitors) was shown in red, closely located to the orthosteric binding site. Also shown was a non-allosteric
inhibitor (green, projected from PDB 1HCK) and an allosteric inhibitor (red, projected from PDB 3PY1). Finally cyclin-A was visualized pairing (light




The physicochemistry and topography of ligand binding
sites is generally conserved amongst related proteins,
however, comparisons of the pharmacology of related
targets (and even the same target) are often confounded
by the existence of multiple, distinct, binding sites within
the same protein. Importantly, these multiple binding sites
can have ‘druggability’ or selectivity properties, and can
therefore offer attractive novel approaches to develop new
therapeutic agents. In this paper, sets of known ligands
binding to the same target are classified as being either
allosteric (binding at a site that is non-competitive for a
natural ligand/substrate) or non-allosteric (binding at the
same site as a natural substrate), it is demonstrated that
there are differences in the profiles of ligands discovered
empirically against these sites. Finally predictive models
are developed with several useful applications in drug
discovery.
Allosteric Modulators in ChEMBL
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can even be used to distort protein-protein interactions [24–26]. In
all of these cases allosteric modulators can allow modulation of
these targets by small molecules using well-established medicinal
chemistry and drug delivery strategies.
Furthermore, allosteric modulators are interesting from a phy-
siological viewpoint, as they provide a way to modulate natural
regulation (amplify a naturally regulated response) rather than
completely inhibit or continuously activate proteins. Orthosteric
drugs activate or inhibit a protein in a dose dependent manner.
Yet allosteric drugs can differ, while their concentration in the body
is dose dependent, their effect can be dictated only by concen-
tration but can also be dictated by concentration in combination
with physiological signaling and feedback loops [15].
Finally, in GPCR signaling allosteric modulators have been
shown to possess other advantages over orthosteric ligands due to
functional selectivity displayed by these allosteric ligands. Func-
tional selectivity is expected to lead to greater selectivity and safety
of drugs targeting GPCRs [27].
However, there are also less favorable characteristics of allo-
steric modulators making them less suitable as drugs. By definition
allosteric modulators inhibit non-competitively and often via a
secondary binding pocket. Hence the shape and pharmacophoric
properties of such a pocket are not necessarily as highly conserved
across paralogs and orthologs, as a catalytic/substrate site would
be. The former site will usually not be under the same selective
evolutionary pressure for protein function as the latter [28]. In the
case of viral inhibitors or any other systems where rapid genetic
mutation and selection is possible (e.g. anti-fungals, anti-bacterials
and anti-cancer therapeutic areas), the use of allosteric modulators
might lead to easier onset of resistance by point mutations. This is
empirically the case of the non-nucleoside reverse transcriptase
inhibitors (NNRTI) used in the treatment of infections with the
Human Immunodeficiency Virus (HIV). NNRTIs are well known
for a quick onset of (cross) resistance [29]. Moreover, they are only
effective on the HIV-1 subtype and not on the closely related HIV-
2 subtype (61% identical when comparing HIV-1 strain M with
HIV-2 strain A). In HIV-2 the allosteric pocket cannot be formed
due to the presence of substitutions native to HIV-2, which lead to
NNRTI resistance in HIV-1. Conversely, non-allosteric inhibitors
are effective on both strains due to their similarity to the natural
ligands [29,30].
Improvement of bioactivity models
Public resources like ChEMBL [31], Pubchem [32], BindingDB
[33], and Drugbank [34] have transformed many parts of drug
discovery. The availability of the data enables new research into
signaling processes and the ligand – target bioactivity space [35–
37]. For example, computational models can be developed using
existing compound structure and activity data, and used to predict
potential activities for other compounds. Hence this data opens the
door for new applications like in silico side effect prediction,
personalized medicine and rational design of polypharmacological
drugs [38–40]. However the presence of multiple binding sites and
binding modes potentially confuses and frustrates model develop-
ment and validation in cases where multiple binding sites exist.
Consequently the ability to distinguish between mode of action
and systematic characterization of these compounds could
potentially prove invaluable in drug discovery.
Aim of the work
In this work a top down analysis of allosteric modulators in the
ChEMBL database was applied. Sets of ligands from papers in
ChEMBL-14 were classified as being either allosteric, or non-
allosteric (or presumed orthosteric) based on keywords, which were
identified in both title and/or abstract. From the resulting papers
the primary target was identified and then the compounds
associated with this target were retrieved.
The resulting sets of ligands (allosteric and non-allosteric) are
information dense (containing annotated target information, bio-
activity, and the source documents). This information is subse-
quently exploited to study the allosteric concept over all bioactivities
in ChEMBL, but also on a per target basis. Finally trends describing
the chemistry, targets and bioactivity of compounds annotated to be
allosteric are extracted
Results/Discussion
Composition of data sets
Allosterism has been reported in the ChEMBL database since
the first indexed papers in 1980 (although the concept has been
around in literature since the 1960’s) [12,13]. In total 987 unique
documents were retrieved that together form the allosteric set
(after manual curation for the case studies this number rises to
1,002). Likewise a non-allosteric set was retrieved, this set consisted
of the documents that were not pulled in the first set and included
the same restraints as applied to the allosteric set (see Methods).
Finally a balanced non-allosteric set was derived from the full
non-allosteric set to better perform unbiased classification. This
balanced set was more similar in raw size and target distribution to
the allosteric set (Table 1).
The allosteric records made up only a small fraction of the total
records (around 3–4% of the total, Figure 2). However a trend was
seen that the number of allosteric records have been increasing
since the early 90’s with a peak in 2009–2010. Possibly this
increase was caused by the recent focus on allosteric modulation of
GPCRs [14,15,17,41,42]. While the total number of allosteric
records in 2012 was lower, this was likely caused by the fact that
ChEMBL-14 does not contain an entire years’ worth of 2012
publications. The full datasets are available for download on www.
gjpvanwesten.nl/allosterism or ftp.ebi.ac.uk/pub/databases/chembl/
Allosterism as are lists of all identified allosteric and non-allosteric
activity_ids in ChEMBL-14.
Target distribution
The next obvious question was: what targets are amenable to
allosteric modulation? This information could be useful in
assessing the likelihood of finding an allosteric modulator for
related targets, and can also be input to screening or assay
strategies. Ideally this information leads to insights how theses
targets differ from the targets preferentially interacting with non-
allosteric modulators. Since allosteric modulators are sometimes a
secondary approach when non-allosteric modulation is infeasible
or impossible, the expectation would be that the target distribution
is different. Recently, Li et al. published work where they studied
targets that can be allosterically modulated [43]. Yet, their work
was limited to targets with known crystal structures, and hence
would suffer from a systematic bias to simpler globular proteins.
Here this was taken a step further investigating all allosterically
modulated literature targets that are retrieved from ChEMBL.
The targets in ChEMBL are classified within a hierarchy, in which
level 1 (L1) denotes the protein type (e.g. ‘Membrane Receptor’ or
‘Enzyme’), L2 further narrows the protein family (e.g. Class A
GPCR known as ‘7TM1’) and so forth down to individual proteins
(supporting Figure S1) [31].
Distinct differences were identified in the distribution of target
classes when the total number of bioactivity measurements
retrieved per target class was considered (L2 target distribution
for both data sets, Figure 3). While the major target classes known
Allosteric Modulators in ChEMBL
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from medicinal chemistry literature were represented in both sets
(e.g. class A GPCRs and Proteases) their distribution differed
between sets, moreover there were major differences [4]. For
instance class C GPCRs were enriched among the allosteric set, as
were the Nuclear Receptors and the Ligand-Gated Ion Channels.
For class C GPCRs it has traditionally been difficult to obtain
selectivity using non-allosteric ligands as these ligands tend to be
very small [41]. The tight structure-activity relationships observed,
Table 1. Data set composition.
Allosteric Non-Allosteric (Balanced) Non-Allosteric (Full)
Years 1980–2012 1980–2012 1980–2012
Documents 1,002 8,315 21,494
Data points 18,281 18,035 409,869
Assays 2,111 9,938 41,416
Binding assay derived 82% 81% 86%
Functional assay derived 17% 19% 13%
Other 1% 0% 1%
Targets 417 1,869 2,935
L1 target classes 10 13 13
L2 target classes 17 17 22
Compounds 17,829 17,709 384,288
Small Molecules 97% 96% 92%
Biologicals 3% 4% 8%
Organic (Small Molecule) 100% 99% 100%
Inorganic (Small Molecule) 0% 1% 0%
Peptide (Biological) 62% 46% 42%
Composition of the data sets generated. The allosteric set was obtained via text mining of abstracts; the non-allosteric (Full) set was the remainder of ChEMBL obtained
using the same constraints as the allosteric set (e.g. limit bioactivity to primary assay). The non-allosteric (balanced) set was derived from the non-allosteric (full) set by
taking a random percentage of each L2 target class present in the allosteric set. The classes ‘Organic’ and ‘Inorganic’ were subsets of the ‘Small molecules’ class.
‘Peptide’ was a subset of the ‘Biologicals’ class. Abbreviations: L1 – Level 1 target classification, L2 – Level 2 target classification.
doi:10.1371/journal.pcbi.1003559.t001
Figure 2. Distribution of retrieved allosteric and non-allosteric publications sorted per year. Overall the allosteric records made up a
small fraction of the total records in ChEMBL-14. However a slight upward trend was seen. Note that the y-axis is logarithmic.
doi:10.1371/journal.pcbi.1003559.g002
Allosteric Modulators in ChEMBL
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centered around very ligand efficient recognition of the natural
effector ligand do not allow much opportunity for variation in the
receptor sequence and consequently in synthetic ligands biding
this site (e.g. Metabotropic glutamate receptors, GABAB receptors,
etc.). However it has previously been shown that selectivity can be
obtained using allosteric modulation and this course of action has
been pursued in the literature and was hence represented in the
data set [17,41,44]. The overrepresentation of GPCRs was
expected as it has previously been shown that GPCRs are targets
typically readily accessible to allosteric modulation [16,42,45]. A
similar plot has been created for the L1 target class, which can be
found in the supporting information (supporting Figure S2).
Chemical structure properties
Similar to the target-based overview of allosteric versus non-
allosteric compounds, the chemical properties of both classes of
compounds were investigated to highlight differences (Figure 4A).
The two most important observations were that historically
identified allosteric modulators tend to fall within a much more
narrower range of molecular weight (but are a subset of non-
allosteric compounds rather than distinctly separated from non-
allosteric compounds) and secondly that allosteric modulators
adhered slightly better to Lipinski’s rule of 5 (75% versus 66%).
Yet the important observation here was that the literature does not
contain much information about allosteric modulators that are far
from drug-like space. However, the relative scarcity of non drug-
like allosteric modulators does not mean that these are not possible
(e.g. the peptidomimetic kinase inhibitors). A similar observation
has been made by Wang et al. yet some examples of allosteric
modulators outside drug-like space were retrieved here, contrary
to their work [11]. One possible explanation for this lack of non-
drug-like allosteric modulators could be based on the bioactivity
statistics of allosteric modulators (see below).
The differences between allosteric modulators and non-alloste-
ric modulators were further explored in Figure 4B where
normalized activity was also included (based on a negative log
value of IC50, EC50, Ki and Kd values). Overlap was observed in
the high affinity locations shared by allosteric and non-allosteric
ligands in a scatter plot showing compound fractional polar sur-
face area and molecular solubility. Yet non-allosteric compounds
also showed high affinity at fractional polar surface and molecular
solubility values outside the values preferred by the allosteric
compounds. From these observations it was concluded that the
allosteric modulators in literature form a more restricted range
subset (in the sense of physicochemical properties) from the overall
set of compounds.
Combined, these results demonstrate that allosteric compounds
are not distinct from non-allosteric compounds, however, given
historical data, they appear to form a subset of the broad non-
allosteric compounds (or medicinal chemistry derived compounds).
The results also showed that allosteric compounds on average had
a larger similarity between allosteric sets binding different target
classes than between non-allosteric compounds binding different
target classes (when considering physicochemical properties). The
differences were further demonstrated using a case study where the
chemical differences are relatively large between the two sets.
Case Study 1: Class B GPCRs
As touched upon in the introduction, the desirability of allosteric
modulators for a certain target is not only governed by phys-
iological or pharmaceutical demands. There are cases where
orthosteric modulation is not feasible for the development of orally
active small molecule drugs. Example cases are the class B GPCRs
for which the natural effectors are polypeptide ligands of typical
length ranging 30 to 40 residues [25,46]. There are many func-
tionally and genetically validated links to pathology for this target
Figure 3. L2 target class distribution of both the allosteric (A) and non-allosteric data (B) sets. The distribution of the target classes
differed between the two sets; which confirmed that targets that are easy to hit via non-allosteric inhibitors are not necessarily easy to hit via an
allosteric modulator and vice versa. Abbreviations: 7TM1 - Class A GPCRs, 7TM2 - Class B GPCRs, 7TM3 - Class C GPCRs, IP3 - Inositol triphosphate
receptors, KIR - Killer-cell Immunoglobulin-like Receptors, LGIC - Ligand Gated Ion Channels, RYR - Ryanodine Receptors, SUR - Sulfonylurea
Receptors, TRP - Transient receptor potential channels, VGC - Voltage Gated Ion Channels.
doi:10.1371/journal.pcbi.1003559.g003
Allosteric Modulators in ChEMBL
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class, and a number of drugs are available (some examples are iv/
sc dosed - Calcitonin (Miacalcin), Exendin-4 (Exenatide), and
PTH (Forteo)) [25,47–49]. This target class was represented
approximately equal in both the allosteric and non-allosteric data
set (0.3% of the allosteric and 0.6% of the non-allosteric papers).
While no large differences were apparent in the target distribution,
the physicochemical properties of compounds annotated as
allosteric modulators differed from those annotated as non-
allosteric modulators. Figure 5 summarizes some of the findings
for the class B GPCRs as retrieved from the data set. A figure with
all 68 descriptors used (supporting Table S1) is also available
(supporting Figure S3). In addition all data is available in tab
delimited text format on www.gjpvanwesten.nl/allosterism or ftp.
ebi.ac.uk/pub/databases/chembl/Allosterism. Here a limited
figure is displayed for reasons of clarity.
Differences in physicochemical properties were found for
allosteric and non-allosteric class B ligands (Figure 5). The non-
allosteric (peptide like) ligands were very large (Mwt range 334 Da
to 3591 Da for 95% of the data) whereas those ligands annotated
to be allosteric modulators were ‘classical’ small molecules (Mwt
between 305 Da and 569 Da for 95% of the data). Hence, dif-
ferences were observed in properties related to size like: the number
of chains or the number of hydrogen bond acceptors. However,
when corrected for the size of the ligands, the differences were less
distinct (e.g. carbon fraction of the total atoms). Interestingly the
allosteric ligands were more rigid as indicated by a higher sp2
hybridized carbon fraction, lower sp3 hybridized carbon fraction,
higher aromatic bonds fraction, and higher rigidity index (see
methods for a further explanation of the rigidity index). Allosteric
ligands tended to pass the Lipinski rule of five (60%) and were more
drug-like, whereas non-allosteric ligands were less prone to pass
Lipinski’s rule (30%) and were not drug-like (Figure 5). Finally, the
average formal charge for allosteric ligands was slightly negative and
slightly positive for non-allosteric ligands. Similar charts have been
created for all other significantly populated target classes (L2) and
can be found on www.gjpvanwesten.nl/allosterism or ftp.ebi.ac.uk/
pub/databases/chembl/Allosterism.
Secondary to physicochemical properties, substructures that are
overrepresented in either the allosteric ligands or the non-allosteric
ligands for a target class are of interest. Hence for each target class
all present substructures (using circular fingerprints FCFP_6) were
retrieved and their frequency in the allosteric and non-allosteric
sets were compared against the background of the combined (full)
set. Substructures were then sorted based on the enrichment score
(supporting Table S2, Table S3, and Table S4). The results were
in correspondence with what would be expected considering the
natural ligands for these receptors and the observations from
Figures 4 and 5. Substructures ranking high based on their
allosteric score were quite specific, and tended to be aromatic.
Conversely, substructures ranking very low based on their
allosteric preference were small, frequently occurring and mainly
introducing polarity. Interestingly, substructures scoring high
based on their non-allosteric score included protein backbone like
structures. The full set for all L2 target classes is available as a
download from www.gjpvanwesten.nl/allosterism or ftp.ebi.ac.uk/
pub/databases/chembl/Allosterism.
Bioactivity of allosteric modulators
Protein targets and chemical properties of ligands in the allo-
steric set and the non-allosteric set were the point of focus in the
above text. Now the differences between the bioactivity of allo-
steric compounds and the bioactivity of non-allosteric compounds
are summarized. Considered were: potency (affinity), the number
of targets that compounds from both groups have been tested on,
the number of targets compounds from both groups were active
on, the Ligand Efficiency (LE) [50], and a number of other
Figure 4. (A) Scatter plots showing the molecular weight (x), LogD (y) and adherence to the rule of 5 (color) of allosteric and non-
allosteric compounds. The allosteric compounds represented a subset of the non-allosteric ligands; this image was conserved among most
different target classes. (B) Scatter plots showing the molecular polar surface area fraction (x), solubility (y) and activity (color; pKi, pKd, pIC50, pEC50,).
The area of high activity was observed to be narrower in the allosteric set versus than non-allosteric set. The non-allosteric compounds could display
high affinity along a broader range of both properties.
doi:10.1371/journal.pcbi.1003559.g004
Allosteric Modulators in ChEMBL
PLOS Computational Biology | www.ploscompbiol.org 6 April 2014 | Volume 10 | Issue 4 | e1003559
efficiency indices (Binding Efficiency Index (BEI), Surface Effi-
ciency Index (SEI), Normalized Surface Efficiency Index (NSEI),
etc. [51,52](Table 2)
The median potency was lower for allosteric modulators than
for non-allosteric modulators (5.96 log units versus 6.66 log units,
p,0.01). Moreover, a lower fraction of the compounds was
considered ‘active’ (33% versus 47%), with activity being defined
operationally as potency better than micromolar (6 log units) or
annotated ‘active’ in the source data. Likewise a higher fraction
was inactive (39% versus 29%, less than 6 log units or annotated
‘inactive’ in the source data). Allosteric modulation is a process
that cannot be explained by only ligand affinity (the dynamics are
much more complicated and the reader is referred to a number of
reviews) [53,54], yet the current findings with regard to affinity are
discussed here given the importance of this measurement in drug
discovery.
Several possible explanations for the observed differences can be
considered. Firstly, it is known that metabolites can be allosteric
regulators and these metabolites can be present locally at very high
concentrations and can hence exert their effect with a relatively
low potency. Table 2 could implicate that the data set reflects the
presence of metabolites in our dataset, annotated as allosteric
ligands. High concentration metabolites would not need micro-
molar affinity when they are present at a millimolar concentration
locally [8,55,56]. Secondly, another explanation can be that the
optimization of high affinity allosteric binders is more challenging
given the more constrained chemical characteristics that allosteric
modulators display compared to non-allosteric modulators. How-
ever, there are two more likely but also more complex potential
explanations for the observed lower affinity as will be described below.
Rationalizing the observed lower affinity of allosteric
modulators
A third explanation for the observed lower affinity could be
derived from observations in the field of GPCRs. The current work
is not the first to observe a lower affinity for allosteric modulators
compared to non-allosteric interactions, in particular in the field of
GPCRs this has been observed before [54]. While GPCRs are a
complex modeling system given the baseline presence of both an
orthosteric (natural ligand) and allosteric (G protein) binding site in
all GPCRs, there are some observations that can perhaps be
translated to a more general view of allosterism. It has been shown
that allosteric interactions have a direct effect on the affinity of non-
allosteric ligands (orthosteric in GPCRs) [54]. Given that affinity is
defined as the ratio of ligand association to ligand disassociation
rates, allosteric modulators directly affect the non-allosteric
(dis)association rate. However, the allosteric interaction between
two sites has been shown to be reciprocal [54], hence the affinity of
allosteric modulators is influenced by the affinity of non-allosteric
modulators. As such the observation of the lower affinity of allosteric
modulators might be a product of the dominant usage of radio-
ligand binding assays (as follows). Typically radio-ligand binding
assays are set up using a well-known ligand, a radioactive molecule is
synthesized based on this ligand and the binding of uncharacterized
Figure 5. Mean value (and standard deviation) of several physicochemical properties calculated for both allosteric and non-
allosteric ligands of Class B GPCRs. To plot all properties within one order of magnitude, a number of properties were scaled, dividing the mean
value by 10 (e.g. logP) or by 1000 (e.g. molecular weight). Differences occurred for properties related to size (e.g. molecular weight, number of chains,
number of hydrogen bond acceptors). However properties that were not correlated to size showed smaller differences (e.g. fraction of carbon). Note
that the allosteric compounds were more rigid (higher sp2 hybridized carbon fraction, higher aromatic bonds fraction, higher rigidity index). For the
full figure see supporting Figure S3.
doi:10.1371/journal.pcbi.1003559.g005
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molecules is explored through their effect on the radio-ligand. Given
that the radio-ligand is usually a well-known ligand, it is often a
ligand with a reasonably high affinity. Hence this high affinity effect
might influence the observed affinity of allosteric ligands due to the
reciprocal nature between the binding site of an allosteric ligand and
a non-allosteric ligand. When comparing competitive inhibition
between two non-allosteric ligands (radio ligand and unknown
molecule) this effect will likely not be present. While this explanation
is funded on observations from the field of GPCRs, it should be
noted that in this field allosteric modulation has arguable been the
most intensely explored.
Another observation from the field of GPCRs is that ligand
efficacy does not necessarily correlate to ligand affinity. There is
documented evidence in literature wherein the ligand with the best
affinity does not display the best efficacy [57,58]. It has been
hypothesized that this discrepancy can partially be explained
through the concept of binding kinetics. For a number of GPCRs
it has been found that efficacy is better explained when receptor
residence time or disassociation rate is considered (the most effi-
cacious ligands are shown to be the ligands with longer residence
time) than when only affinity is considered [57–59]. In the case of
allosteric modulators a similar principle might apply. Indeed, cases
in which allosteric modulators modify binding kinetics of non-
allosteric ligands have been described in literature [60,61]. Given
that we observe here that allosteric modulators tend to be rela-
tively small and lipophilic molecules one can expect de-solvation to
play a major role in binding kinetics. Hence these molecules might
display a baseline longer residence time than non-allosteric mole-
cules due to their physicochemical properties. However, further
research and experimental evidence is required to confirm or
reject this hypothesis.
Implications for assays focused on allosteric modulation
While any classification into ‘active’ or ‘inactive’ is based on a
cut-off, the observations here regarding affinity illustrate a larger
issue. In screening efforts cut-offs are important to retrieve
interesting ligands. If the median potency of allosteric modulators
is lower than that of non-allosteric modulators (corroborated by
the tendency of allosteric ligands to be smaller, to be more
lipophilic, and to possess less hydrogen bonding potential) this
could very well lead to possible allosteric modulators being missed
in screening efforts. The general threshold for activity in primary
screening is 10 mM to find compounds that are shown to have a
median activity of 6.66 log units in ChEMBL. Hence, the
implication would be that any screening effort for allosteric
modulators (median activity of 5.96 log units) would need to be
more sensitive or at least have the definition of ‘active’ adapted to
conform to our observations. Moreover, given the reciprocal
nature of the effects that allosteric and non-allosteric sites have on
each other, it would be recommended to not use a single radio-
ligand if one is aiming to find new allosteric modulators. A better
choice is to use a spectrum of assays with different radio labeled
ligands as has also been suggested by May et al. [54].
That said, allosteric compounds were found to have similar but
slightly higher median binding efficiency indices (LE, BEI, SEI,
NSEI), this difference was likely caused by the fact that allosteric
modulators tend to be smaller than non-allosteric modulators.
This potentially indicates on average smaller, less polar binding
sites for allosteric versus non-allosteric classes [43]. Moreover, we
observed that allosteric modulators tend to have been annotated to
a lower number of targets (2 versus 3) but this difference is
marginal. Additionally, the median number of targets a compound
is active on is shown to be 1 (average 1.43) for the non-allosteric
set, in line with the findings of Hu and Bajorath [62], but the
values are median 0 (average 1.40) for the allosteric set.
In conclusion, allosteric modulators were found to be able to
modulate targets with low affinity but high efficiency. In addition,
the data did not show allosteric modulators to be inherently
promiscuous binders – at least as inferable from the distribution
of assays reported in ChEMBL –, rather there was a trend for
Table 2. Bioactivity measurements for allosteric and non-allosteric compounds.
Allosteric Median (MAD) Non-Allosteric Median (MAD)
Activity 5.96 (61.02) 6.66 (61.17)
LE 0.319 (60.0723) 0.310 (60.0689)
BEI 16.3 (63.69) 15.9 (63.55)
SEI 11.1 (64.12) 10.3 (63.82)
NBEI 0.233 (60.0528) 0.226 (60.0503)
NSEI 1.16 (60.370) 1.08 (60.348)
nBEI 7.34 (61.06) 8.12 (61.19)
mBEI 8.49 (61.06) 9.27 (61.19)
Targets Annotated 2 (61) 3 (62)
Targets Active 0 (60) 1 (61)
Targets Inactive 1 (61) 1 (61)
Targets Other 1 (61) 1 (61)
Actives (%) 33 47
Inactives (%) 39 29
Other (%) 28 24
A threshold of 6 log units was used to classify compounds as ‘active’. Abbreviations: MAD – Median Average Deviation, LE – Ligand Efficiency (kcal/mol per non-
hydrogen atom), NBEI – Normalized Binding Efficiency Index (non-hydrogen atoms), BEI – Binding Efficiency Index (molecular weight), SEI – Surface Efficiency Index
(polar surface area/100), NSEI – Normalized Surface Efficiency Index (polar atoms), nBEI – Normalized Binding Efficiency Index taking the log after calculation of the ratio
(non-hydrogen atoms), mBEI – Normalized Binding Efficiency Index taking the log after calculation of the ratio (molecular weight). See Abad-Zapatero et al. [52].
doi:10.1371/journal.pcbi.1003559.t002
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allosteric compounds to be less promiscuous than non-allosteric
modulators, which is also seen in previous work [43]. While the
potential of the current data set is demonstrated by comparing the
allosteric and non-allosteric set, this analysis is by no means
exhaustive. Similar analyses can be performed comparing different
allosteric sets or for instance comparing class C GPCR ligands from
the allosteric set with the class A GPCRs of the non-allosteric set
(comparing two different sets of trans-membrane domain binding
ligands). Moreover, it should be noted that further research is
required to determine if the lower binding affinity observed results
from database bias or if this is an intrinsic property of allosteric
modulators (and if so, what the cause is of this observation).
Allosteric classification models
Above it was shown that there are chemical differences between
allosteric ligands for a certain target class and non-allosteric ligands
for that same target class. In some cases these differences were large
(as in the case of class B GPCRs) whereas in other cases the
differences appeared to be smaller (as in the case of class A GPCRs).
These chemical distinctions were used to train a classification model
that would be able to predict if a compound would likely be an
allosteric modulator or a non-allosteric modulator for a given target
based on the physicochemical properties. These models were
created on the balanced set to avoid a large bias in classifier
predictions (Table 1). Non-balanced models have also been trained
and data is available in the supplementary information.
The use of (circular) fingerprints in the full (non-target specific)
models was sidestepped for several reasons; firstly these models
should have a large applicability domain and should hence not be
limited to certain chemical motifs. Secondly, (chemical) sampling
bias of specific historical target classes was to be avoided. Thirdly,
the large chemical diversity would probably make those features
that are predictive very generic (as shown in the class B GPCR
case study for substructures negatively associated with allosteric
modulators, supporting Table S2, S3, S4). Finally the improve-
ment of circular fingerprints to the models was marginal (on
average 5% as calculated by the average of the used parameters,
supporting Table S5). Hence circular fingerprints were only used
in more congeneric chemical sets (e.g. target specific) [63]. Models
were judged by recall of allosteric modulators (Sensitivity (sens));
recall of non-allosteric modulators (Specificity (spec)); precision for
allosteric modulators (Positive predictive value (PPV)); precision
for non-allosteric modulators (Negative predictive value (NPV));
and Matthews correlation coefficient (MCC). These were all 0 for
a non-predictive/random model and 1 for an ideal model with the
MCC also potentially being -1 for an ideal inverse model (see
Methods for further details).
Table 3 shows a selection of the results for allosteric classi-
fication models (each trained on 70% of the data and externally
validated on the remaining 30%). For the full table see supporting
Table S6, here we limited ourselves to a single page for reasons of
clarity. Different models on data sets grouped by class L0 (protein
binding compounds), L1 (first level classification), and L2 (second
level classification) have been trained. Figure 6 shows the out-of-
bag ROC curve and external validation for the L0 model. For all
groups models were able to classify a compound as allosteric
modulator or non-allosteric modulator of a given target class with
good accuracy, yet model performance improved when sets
became more specific (limited to a target class). These models
provide a useful tool for the elucidation of the mechanism of action
for compounds identified in primary HTS screening efforts.
Second to being able to predict if a compound will or will not be
an allosteric modulator, it is also of interest to find out what
properties are important to make this distinction. Given in Table 3
are the three most important properties that were correlated with
the ‘allosteric’ class and the three most important properties that
were correlated with the ‘non-allosteric’ class for each classification
model. These properties allow the further investigation into what
differentiates allosteric from non-allosteric compounds. While in
most cases allosteric modulators were more lipophilic and non-
allosteric compounds were associated with a higher polar surface
area this was not always the case. Examples were the Transient
Receptor Potential Channels (TRP) and Voltage Gated Ion
Channels (VGC) target classes (L2 target class, ion channels), part
of the Ion Channel (L1 target class). Here allosteric ligands had a
larger polar surface area (TRP) or larger polar solvent accessible
surface area (SASA) (VGC). Conversely non-allosteric ligands
were more rigid (TRP). No explanation for this observation is
currently available but possibly, in the case of these two ion
channels, the uncompetitive binders could bind near the ion
channel itself and hence resemble these ions that are transported
by these proteins rather than resembling the natural regulators
(which is Voltage in the case of VGC and can be diverse in the
case of TRP). Note that this observation was absent for the Ligand
Gated Ion Channels (LGIC) where the allosteric modulators seem
to correspond more to what we observe in other protein classes
(double bonds are favorable and solubility/positive atom fraction
are not favorable). For the full table containing the results of all
classification models trained on all targets in levels 0–2 (including
class ‘undefined’ models) see supporting Table S6. In the final
section the potential of the data set is demonstrated using three
further different case studies.
Case Study 2: HIV reverse transcriptase
To illustrate possible applications of the data set, the classifi-
cation models were applied to a number of previously studied
targets for which a range of allosteric inhibitors has been
published. The first of these targets is the viral enzyme HIV-1
reverse transcriptase (HIV-RT), for which substantial SAR data
and several approved drugs are well established [64,65]. A
relevant drug target in the treatment of HIV, this target will fall
into ‘Enzyme’ L1 target class and is not further defined on lower
target class levels due to the sparseness of other related proteins in
version 14 of ChEMBL. Importantly, both allosteric and non-
allosteric drugs have been successfully developed as therapeutics,
and many co-crystal structures reported clarifying the binding sites
of various compound classes, making this an ideal target case.
Furthermore rational design and random screening have been
used to extensively study the protein.
Before training models the molecules were clustered based on
FCFP_6 fingerprints. As can be expected there were some mis-
classifications in the dataset. Known allosteric compounds were in
the non-allosteric training set (sharing scaffolds with known
allosteric inhibitors). Moreover, a number of compounds in the
allosteric training set were noted to be non-allosteric compounds
(nucleotide like structures) and vice versa. Capturing this unan-
notated, or tacit knowledge within a field is challenging, and
highlights some issues with data-mining the literature where ad
hoc vocabularies and conventions are used; however, it also
highlights the opportunity and added value for further curation.
The clusters containing these compounds were reclassified based
on the information in the original publications and subsequently a
model was trained (Table 4). The model performed well with a
sensitivity of 0.89, specificity of 0.88, PPV of 0.92, NPV of 0.84
and MCC of 0.76 and was hence interpreted (Figure 7).
The HIV-RT allosterism model showed the three most
important descriptors for non-allosteric compounds to be fraction
of Oxygen atoms as a part of all atoms (for instance the presence of
Allosteric Modulators in ChEMBL
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a ribose moiety or a number of phospho groups contributes to this
descriptor), a larger polar surface area and a larger fraction of
atoms that are H-bond acceptors. Conversely, the following
parameters were found to be predictive for allosteric ligands: a
larger fraction of the bonds should be aromatic, the fraction of
bonds that are ring-bonds should be higher and the distribution
coefficient (LogD) should be higher (for a top 20 list see supporting
Table S7). These results demonstrate that the here-published data
set is a suitable starting point to create a model that can
differentiate between likely non-allosteric and likely allosteric
ligands for a specific target. However, after further data set cura-
tion this approach can lead to a well performing model that can
reliably differentiate between these classes. This approach to
developing a predictive method for allosterism is however not
limited to enzymes as is shown in the following examples.
Case Study 3: Adenosine receptors
Like HIV-RT, the class A GPCR adenosine receptors form a
highly validated and important drug target, where both agonists
and antagonists have a therapeutic potential. Moreover, there is
now structural data for this GPCR target. Adenosine receptors are
relevant targets in the treatment of diabetes and Parkinson’s
disease [66]. Allosteric modulation of the adenosine receptors has
anticipated advantages over orthosteric modulation as it is
expected to increase tissue specific selectivity and enable modu-
lation of receptors present in the brain [66]. Moreover, class A
GPCRs make up a large fraction of the targets present in
ChEMBL. This is due to their high relative tractability, the
historical research effort on this class, the large size (ca. 300 family
members in the human genome), and linkage to many important
diseases [4]. However, unlike HIV-RT no allosteric modulators of
adenosine receptors have yet been launched as drugs. One
compound, T-62, was under evaluation for the treatment of
chronic pain but crashed out in phase 2 trials [67]. Moreover,
there is a preclinical body of work that demonstrates allosteric
modulation for these drug targets and hence they were chosen to
be included here as a case study. Different from the HIV-RT case
study is that here a group of closely related proteins is used rather
than a single target. Hence it is shown that the current data set can
also be used to capture properties that distinguish allosteric
modulators for a family of targets.
Again some manual curation was needed before moving to
model training. The main finding was the paper by Narlawar et al.
[68]. This paper describes bitopic ligands that possess both
allosteric and non-allosteric domains. The compounds were
marked as allosteric due to the keywords noted in the abstract,
yet the large non-allosteric part of the ligands (including a ribose
moiety) deteriorates model performance. Similarly a number of
ligands described by Jacobson et al. were included in the allosteric
set as the abstract mentions that only some compounds appeared
to bind at an allosteric site, yet the majority of the 78 compounds
were non-allosteric, hence these were also cleaned [69].
The adenosine receptor allosteric modulator model performed
well (sens 0.94; spec 0.97, PPV 0.66; NPV 1.00; and MCC 0.77;
Figure 7), although the lower PPV lead us to believe further
curation might improve model performance. The model was then
interpreted. Allosteric ligands had a higher fraction of aromatic
bonds, a higher LogD, and a higher average bond length
compared to non-allosteric ligands. Whereas non-allosteric ligands
had a higher heteroatom fraction and a larger polar surface area
compared to allosteric ligands. Yet there was an interesting
distinction with the HIV-RT models. The structures of known
adenosine ligands (both allosteric and non-allosteric) are much
more conserved than those of HIV-RT ligands. Hence structural
features (in this case FCFP_6 substructures) were much more
important in model creation compared to generic physicochemical
properties (for example a xanthine scaffold was found to be
correlated with non-allosteric modulators, supporting Table S8).
Three substructures were shown to have high importance values in
model creation (meaning that model quality significantly de-
creased by leaving them out of the descriptor set).
Case Study 4: Kinase modulators, protein Kinase-B
A fourth and final case study presented in this paper is protein
Kinase-B (PKB)/Akt 1. This enzyme target is relevant in oncology
as it plays an important role in cellular survival pathways by
Figure 6. (A) Receiver Operator Characteristics (ROC) curve for out-of-bag validation of the allosteric classifier trained on 70% of
the allosteric and balanced orthosteric set demonstrated good performance. (B) External validation on the remaining 30% of the data set
confirmed good predictive performance.
doi:10.1371/journal.pcbi.1003559.g006
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inhibiting apoptotic processes [70,71]. PKB differs from the
previous targets as two different classes of allosteric modulators
have appeared in the literature. As touched upon in the
introduction, allosteric modulators of kinases can be small
molecules that act for instance by shifting the balance of protein
dynamics (e.g. locking a protein in an inactive conformation).
However in the case of kinases where orthosteric modulators are
defined as ATP-competitive, allosteric modulators can also be
compounds that resemble the substrate of the kinase and hence be
peptides (protein like compounds). In the current case study the
allosteric modulators hence make up two major classes, one of
which are large peptide like compounds. As such Protein Kinase B
is an interesting target that forms the inverse of the class B GPCRs
mentioned above. The non-allosteric modulators in this case were
all ATP-competitive and it was hypothesized that this class forms a
group that is more similar chemically than the allosteric
modulators. Given the clear distinction between allosteric modu-
lators that are peptidomimetic and small molecule allosteric
modulators, the chosen course of action was to train the model
using a three-class model rather than a binary classification model.
The model had good predictivity (sens 0.96; spec 0.94; PPV 0.71;
NPV 0.99; and MCC 0.86; Figure 7); the added third class,
‘allosteric biological’, was predicted very well with recall 1.00 and
predictive value 1.00.
As expected, properties mostly related to size (Molecular polar
surface area, volume) were correlated with the biological allosteric
modulators as is the ChEMBL calculated molecular class
‘biological’. The physicochemical properties mostly correlated
with small molecule allosteric modulators were number of chain
assemblies, ringbond fraction, carbon fraction, and number of sp2
hybridized carbons. Additionally the ChEMBL calculated molec-
ular class ‘small molecule’ was correlated to small molecule allo-
steric modulators. Interestingly, properties Lipinski pass, aromatic
bonds frac, ringbonds frac, and LogD were also correlating with
non-allosteric modulators (contrary to the trends observed in other
targets). This is likely due to the fact that ‘small molecule allosteric
modulators’ and ‘small molecule ATP competitive modulators’
more closely resemble each other than they do the ‘biological
allosteric modulators’ in terms of physicochemical properties.
Moreover the non-allosteric/ATP-competitive set contained a
number of drugs, which are highly optimized structures. Yet,
LogD, and ringbonds fraction correlated to both the allosteric and
non-allosteric small molecule classes. Conversely, negative atom
fraction and number of hydrogen bond acceptors were correlated
with only non-allosteric compounds (likely due to the need for
ATP-competitive compounds to also resemble parts of ATP), but
this effect was less pronounced. Also in this case study (similar to
HIV RT) sub-structural features were observed to be very
important. Moreover, in the biological allosteric modulators class
protein/peptide backbone fragments were appearing as important
in combination with charged arginine side chains. Inversely, in the
case of small molecule allosteric modulators the important
substructures mostly contain aromatic rings. For a longer list see
supporting Table S9.
Prospective use of allosteric classifiers
In the case studies the potential of the data set identified and
provided in this paper is demonstrated. The dataset is shown to be
a solid starting point for allosteric focused drug discovery towards
existing targets or towards new targets. With modest further
curation highly predictive models could be obtained. While it is
outside the scope of this paper to provide a case study on all
potentially interesting protein targets, possible other examples
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Alcohol dehydrogenases (e.g. Isocitrate dehydrogenase 1 and 2
(ICDH)) [75], and class C GPCRs [26].
The models obtained here trained on the full allosteric mod-
ulator set should have a broad domain of applicability due to their
generic nature (physicochemical properties were used as descrip-
tors). Hence it is expected that these models are not limited to
certain known chemical motifs as would be the case when using
circular fingerprints. While also outside the scope of the current
paper, the authors would very much welcome a prospective
validation of the models. It should be noted that these models are
solely classifying between ‘a likely allosteric interaction’ and ‘a
likely non-allosteric interaction’. Hence the models cannot be used
to predict the affinity of ligands on certain targets, but are able to
predict the likely type of interaction for a given interaction. As
such these models should ideally be combined with dedicated
bioactivity models that can predict the affinity of molecules on a
certain target and not replace them. Hence the allosteric classifiers
can be used as a secondary filter when selecting compounds from a
chemical vendor to be tested experimentally.
The authors feel that other potential applications could be the
following: Firstly, creation of allosteric focused libraries based on
known chemical properties of allosteric modulators, these libraries
can be further sub divided on target type (e.g. Class A GPCR or
Protein Kinase). Secondly, determination of interaction type of
hits retrieved from HTS screening (allosteric or non-allosteric).
The authors are very open for potential collaborative projects to
experimentally validate the approach as described here. Hence the
authors would urge readers to contact them when they are
interested in a specific set of allosteric modulators.
Conclusions
As stated in the introduction, the term allosteric modulator is a
very broad definition directly depending on the target (class) in
question. Despite the presence of peptidic ligands and very diverse
chemistry, there are some general conclusions that can be drawn
from the current work.
Allosteric modulators tend to be more rigid and lipophilic
structures compared to the background set. This is in line with
their mode of action via binding in distinct structural locations of
proteins rather than catalytic or agonist sites. Yet the magnitude of
these changes in physicochemical properties depends on the target
in question and the non-allosteric ligands. Moreover, it is observed
that allosteric modulators are constrained to a narrower structure
activity window than are non-allosteric modulators. When the
physicochemical properties of allosteric modulators are compared
to all ligands for a target, the allosteric modulators are often a
subset of the non-allosteric ligands.
Secondly, it is observed that allosteric modulators are interesting
drugs for several reasons. They tend to adhere better to Lipinski’s
rule of 5, making them good candidates for oral formulation. This
could indicate that, if allosteric hits are identified for a target,
allosteric ligands are more developable then non-allosteric ligands.
Moreover, a trend is observed that allosteric modulators are less
promiscuous than non-allosteric modulators.
Thirdly, the absolute potency for allosteric modulators is
observed to be lower, while their binding efficiency and surface
ligand efficiency is similar. Some potential causes are discussed
here, but before a qualitative statement can be made about this
observation further research is required. However this observation
does call for the adaptation of screening assays to pick up the lower
affinity compounds.
In conclusion, the differences between non-allosteric and
allosteric modulators for a given target are usually such that it is
not straightforward to turn a non-allosteric compound into an
allosteric compound or vice versa. Yet it is these chemical
differences that allow the creation of classification models that can
distinguish between allosteric and non-allosteric modulators.
These models are shown to perform better if the target definition
is more concise, yet even without these constraints already
predictive models were constructed. Hence non-allosteric and
allosteric inhibition of a single target can be considered different
target classes overall. The work performed here should lead to
improvement of bioactivity models by providing tools to incorpo-
rate binding mode as a descriptor for compounds and hence
reducing the noise present in a data set.
While the authors have demonstrated in the current paper how
the dataset can be used as a starting point for allosteric drug
design, full manual curation of the dataset is at the moment
infeasible. Hence the authors encourage everybody who encoun-
ters an error or misclassification in this data set to contact them so
that curation can take place via crowdsourcing and the quality of
this data in ChEMBL can increase.
Figure 7. ROC curves for out-of-bag validation of the allosteric classifier models trained in case studies 2–4. (A) ROC curve for the HIV-
RT classifier. (B) ROC curve for the adenosine receptors classifier. (C) ROC curve for the Protein Kinase B classifier (note that here a ternary model was
used as opposed to a binary model).
doi:10.1371/journal.pcbi.1003559.g007
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Methods
Data set
The data set was obtained from ChEMBL version 14 [31]. For
the allosteric set, abstracts and titles of journal articles were
searched for keywords (supporting Table S10). For hits both
PubMed ID and citation information (primary author, year,
journal, volume, and starting page) were kept. From these
retrieved records the primary target (based on bioactivity anno-
tation frequency for targets considered in the document) was
included along with all compounds annotated on this primary
target. As a final step duplicate compounds were removed for each
target ID. Herein a distinction was made in the quality of the
bioactivity measurement, best measurements (e.g. pKi) were
favored over lower quality measurements (e.g. activity comment
‘active’). The background set was retrieved in a similar fashion, but
here all document IDs that were not part of the allosteric set were
kept. Finally, the balanced non-allosteric set was retrieved from the
full non-allosteric set by keeping a random percentage of bio-
activities from each L2 target class which was roughly equal in size
to the number of bioactivities present in the allosteric set. All data
is available on www.gjpvanwesten.nl/allosterism or ftp.ebi.ac.uk/
pub/databases/chembl/Allosterism, see supporting Figure S4 for
details.
Compound pre-treatment
Compounds were standardized, charged at a pH of 7.4, salts
were removed and 2D and 3D coordinates were calculated. All of
this was done in Molsoft ICM version 3.7-2d [76].
Compound descriptors
Volume, Polar Surface Area, Molecular weight, and drugLike-
ness were calculated in Molsoft ICM, carbon hybridization states
were calculated using the Perl molecular toolkit in Pipeline Pilot
[76,77]. For partition coefficient (LogP) calculations it has been
shown that consensus methods perform well [78], hence the used
LogP value was the average of AlogP calculated in Pipeline Pilot,
logP according to Molsoft ICM and ACD LogP [76,77,79].
Similarly LogD was the average of the Pipeline pilot module and
ACD LogD, finally solubility was the average of the pipeline pilot
calculator and Molsoft ICM value. The remaining compound
physicochemical descriptors were calculated in Pipeline Pilot using
the chemistry component collection [77]. The Lipinski Pass/Fail
class was calculated allowing no violations. For the individual case
studies additional FCFP_6 descriptors were used, on these
Bayesian feature selection from Pipeline Pilot was applied to
transfer them into a 512 bits fixed bitstring [77,80].
Finally, the rigidity index was an estimation of compound
rigidity that was calculated as follows: (AromaticBonds fraction)+
(1-RotatableBonds fraction)+Aliphatic Ringbonds fraction+(1-Sin-
gleBonds fraction)+DoubleBonds fraction+TripleBonds fraction+
BridgeBonds fraction)/7;
Target pre-treatment
Target information from ChEMBL (Uniprot ID, target
classification) was kept as it was defined in ChEMBL. However,
when target classification levels were unpopulated the value was
replaced with ‘Undefined’.
Machine learning
Models were trained in Pipeline Pilot using the ‘Random Forest’
component. This component uses R-Statistics (version 2.15.0) and
the ‘forest’ package [81,82]. For variable importance selection
permutation based selection and Gini importance without scaling
were used, as recommended by Strobl et al. [83,84]. Important
variables were selected based on Pareto optimization of both
importance values and class correlation values (e.g. correlation
with ‘Allosteric’ class).
Model validation
Validation was performed using 5 different metrics these were:
sensitivity (allosteric recall, the fraction of true positives of the total
number of allosteric compounds), specificity (non-allosteric recall,
the fraction of true negatives of the total number of non-allosteric
compounds), positive predictive value (allosteric precision, the
fraction of true positives of the total number of compounds pre-
dicted to be allosteric modulators), negative predictive value (non-
allosteric precision, the fraction of true negatives of the total
number of compounds predicted to be non-allosteric modulators),
and the Matthews correlation coefficient [85]. Given a confusion
matrix were A represents an allosteric modulator classification and
B represents non-allosteric modulator classification, Sensitivity is
class A recall, and specificity is class B recall, whereas positive
predictive value is class A precision and negative predictive value is
class B precision (Table 5).
For the MCC equation (1) was used; herein the numerator is the
product of the correctly predicted data points minus the product of
the incorrectly predicted data points. The denominator is formed
by the square root (2-classes) of the total product of all possible




(TPzFP) 1 (TPzFN) 1 (TNzFP) 1 (TNzFN)
p ð1Þ
Note that false negatives are missed class A predictions and
false positives are missed class B predictions. Hence this can be
rewritten as follows:
Numerator:
(AA 1BB){(BA 1AB) ð2Þ
Denominator:
((AAzBA) 1 (AAzAB) 1 (BBzBA) 1 (BBzAB))1=2 ð3Þ
Table 5. Binary classification confusion matrix.
Model Predicts A Model Predicts B
Experiment Measures A AA AB Class A recall (Sensitivity) AA/(AA+AB)
Experiment Measures B BA BB Class B recall (Specificity) BB/(BB+BA)
Class A precision (PPV) AA/(AA+BA) Class B precision (NPV) BB/(BB+AB)
Recall values are calculated over the rows and precision values over the columns.
doi:10.1371/journal.pcbi.1003559.t005
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In the case of the three-class model (ternary classification) these
calculations were modified to represent the three-class confusion
matrix. Assume class A to be allosteric modulators, class B to be
non-allosteric modulators and class C to be biological allosteric
modulators. Sensitivity remains the fraction of true positives of the
total number of allosteric compounds (here class A recall), specificity
remains the fraction of true negatives of the total number of non-
allosteric compounds (here class B recall), positive predictive value
remains the fraction of true positive of the total number of
compounds predicted to be allosteric modulators (here class A
precision), and negative predictive value remains the fraction of true
negatives of the total number of compounds predicted to be non-
allosteric modulators (class B precision). Additionally a class C recall
(the fraction of true allosteric-biological predictions of the total
number of allosteric-biological compounds) and precision (the
fraction of true allosteric-biologicals of the total number of
compounds predicted to be allosteric biologicals) are introduced.
It should also be noted that the baseline values for a random model
in a ternary classification model are expected to be around 0.33
(33% correctly predicted compared to 66% incorrectly predicted).
This is lower than the value of 0.50 (50% correct prediction and
50% incorrect prediction) for a binary model. Hence values were
scaled to be directly comparable between the two model types.
Equation (1) was again used for the MCC but adapted to the
ternary matrix (Table 6); the product of the correctly predicted
data points minus the product of the incorrectly predicted data
points forms the numerator. The denominator is formed by the
cube root (3-classes) of the total product of all possible sums of
correctly and incorrectly predicted data points.
The following types are defined:
AB+AC = AX (Missed class A predictions)
BA+BC = BX (Missed class B predictions)
CA+CB = CX (Missed class C predictions)
Hence the MCC can be written as follows:
Numerator:
(AA 1BB 1CC){(AX 1BX 1CX) ð4Þ
Denominator:
((AAzAX) 1 (AAzBX) 1 (AAzCX) 1 (BBzAX) 1
(BBzBX) 1 (BBzCX) 1 (CCzAX) 1 (CCzBX) 1
(CCzCX))1=3
ð5Þ
The MCC still produces values between 1 (perfect prediction), 0
(random prediction) and 21 (anti correlation) and need not be
scaled, contrary to the recall values and predictive values as the full
confusion matrix is considered in absolute numbers when cal-
culating the MCC.
Substructure frequency analysis
Substructures were obtained using pharmacophore feature class
based circular fingerprints (FCFP_6) [63,80]. For all present
substructures, substructure frequencies were obtained from the full
data set (background frequency), the allosteric set per L2 target
(allosteric frequency), and the non-allosteric set per L2 target (non-
allosteric frequency). These frequencies were normalized per set
(substructure frequency as a fraction of the total substructures per
set) to prevent a biased ranking. Subsequently all substructures
were ranked based on their normalized frequency.
Enrichment was calculated based on the logarithm of the nor-
malized ranks quotient (between allosteric and background or
between non-allosteric and background). These final scores were
ranked to obtain the final scored rank.
Supporting Information available
4 supporting figures (Figure S1, S2, S3, S4) and 10 supporting
tables (Table S1, S2, S3, S4, S5, S6, S7, S8, S9, S10) that further
support the findings are available online. In addition, the datasets,
further chemical analyses (per target level), physicochemical
property histograms (for L0, L1, and L2), all model training and




Figure S1 The ChEMBL-14 target hierarchy; shown are the
first three levels where L0 means the full allosteric versus the full
non-allosteric set (protein binding compounds). Descending the
hierarchy leads to a finer grained target classification, which
eventually culminates in individual proteins (L8). The target
distribution overview in the main text is made at target level L2
(red circle).
(TIF)
Table 6. Ternary classification confusion matrix.
Model Predicts A Model Predicts B Model Predicts C
Experiment Measures A AA AB AC Class A recall AA/(AA+AB+AC)
Experiment Measures B BA BB BC Class B recall BB/(BA+BB+BC)







Recall values are calculated over the rows and precision values over the columns.
doi:10.1371/journal.pcbi.1003559.t006
MCC~
(AA 1BB 1CC) (AX 1BX 1CX)
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
(AAzAX) 1 (AAzBX) 1 (AAzCX) 1 (BBzAX) 1 (BBzBX) 1 (BBzCX) 1 (CCzAX) 1 (CCzBX) 1 (CCzCX)3
p ð6Þ
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Figure S2 L1 target class distribution of both the allosteric (A)
and non-allosteric data (B) sets. Also here the distribution of the
target classes differed between the two sets.
(TIF)
Figure S3 Bar chart of all the mean values for all descriptors in both
the allosteric and non-allosteric set of the 7TM2 class (Class B GPCRs).
Note that delimited text files are available on www.gjpvanwesten.nl/
allosterism or ftp://ftp.ebi.ac.uk/pub/databases/chembl/Allosterism.
(TIF)
Figure S4 Layout of the online ftp archive with the extra
supporting information.
(TIF)
Table S1 Physicochemical descriptors used.
(DOC)
Table S2 Examples of positively enriched allosteric substruc-
tures class B GPCR ligands.
(TIF)
Table S3 Examples of negatively enriched allosteric substruc-
tures class B GPCR ligands.
(TIF)
Table S4 Examples of positively enriched non-allosteric sub-
structures class B GPCR ligands.
(TIF)
Table S5 Model improvement when including fingerprints in
model construction.
(DOCX)
Table S6 Allosteric models for balanced data sets of L0, L1, and
L2 groups.
(DOCX)
Table S7 Top 20 property importance for the optimized HIV
RT model.
(TIF)
Table S8 Top 20 property importance for the optimized
adenosine model.
(TIF)
Table S9 Top 17 property importance for the optimized protein
kinase B model.
(TIF)
Table S10 Keywords used to retrieve the allosteric set.
(DOCX)
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